FrancophonIA/ELRC3.0 huggingface dataset:
English: Granulomatosis with polyangiitis and microscopic polyangiitis Riximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).
Slovenian: Granulomatoza s poliangiitisom in mikroskopski poliangiitis Zdravilo Riximyo je v kombinaciji z glukokortikoidi indicirano za zdravljenje odraslih bolnikov s hudo, aktivno granulomatozo s poliangiitisom (GPA, Wegenerjevo granulomatozo) in z mikroskopskim poliangiitisom (MPA).
English: This is because Riximyo can cross the placenta and may affect your baby.
Slovenian: Zdravilo Riximyo namreč prehaja skozi posteljico (placento) in lahko škoduje otroku.
English: • Riximyo will be given to you once a week for 4 weeks.
Slovenian: ga boste prejeli enkrat na teden 4 tedne.
English: This is because some people have a fall in their blood pressure while they are being given Riximyo.
Slovenian: Nekaterim ljudem se namreč med prejemanjem zdravila Riximyo krvni tlak zniža;
English: • eating disorders, not eating enough, leading to weight loss
Slovenian: • motnje hranjenja, nezadostno uživanje hrane, kar povzroči hujšanje,
English: Riximyo is a biosimilar medicinal product.
Slovenian: Zdravilo Riximyo je podobno biološko zdravilo.
English: Following induction of remission with other standard of care immunosuppressants, Riximyo maintenance treatment should be initiated during the 4 week period that follows disease remission.
Slovenian: Po indukciji remisije z drugimi imunosupresivi, ki spadajo v okvir običajnega zdravljenja, je treba vzdrževalno zdravljenje z zdravilom Riximyo začeti v 4-tedenskem obdobju po remisiji bolezni.
English: Riximyo is used for the treatment of granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids.
Slovenian: Zdravilo Riximyo se uporablja za zdravljenje granulomatoze s poliangiitisom (prej imenovane Wegenerjeva granulomatoza) ali mikroskopskega poliangiitisa; daje se v kombinaciji s kortikosteroidi.
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1,000 mg per day is recommended prior to the first infusion of Riximyo (the last dose of methylprednisolone may be given on the same day as the first infusion of Riximyo).
Slovenian: Pri bolnikih z granulomatozo s poliangiitisom (Wegenerjevo granulomatozo) ali mikroskopskim poliangiitisom je pred prvo infuzijo zdravila Riximyo priporočljiva intravenska uporaba metilprednizolona, ki se ga daje od 1 do 3 dni v odmerku 1.000 mg na dan (zadnji odmerek metilprednizolona je lahko uporabljen na dan prve infuzije zdravila Riximyo).
English: Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of Riximyo and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Slovenian: Sočasna/zaporedna uporaba drugih DMARD pri revmatoidnem artritisu Sočasna uporaba zdravila Riximyo in zdravil za zdravljenje revmatičnih bolezni, razen omenjenih v indikaciji in odmerjanju za revmatoidni artritis, ni priporočljiva.
English: What you need to know before you are given Riximyo Do not take Riximyo if
Slovenian: Kaj morate vedeti, preden boste dobili zdravilo Riximyo Ne uporabljajte zdravila Riximyo, če:
English: Based on the population pharmacokinetic analysis of data in 97 patients with granulomatosis with polyangiitis and microscopic polyangiitis who received 375 mg/m2 rituximab once weekly for four doses, the estimated median terminal elimination half-life was 23 days (range, 9 - 49 days).
Slovenian: Na podlagi populacijske farmakokinetične analize podatkov 97 bolnikov z granulomatozo s poliangiitisom in z mikroskopskim poliangiitisom, ki so štiri tedne prejemali 375 mg/m2 rituksimaba enkrat na teden, je ocenjeni mediani končni razpolovni čas izločanja 23 dni (razpon: od 9 do 49 dni).
English: Patients with active hepatitis B disease should not be treated with Riximyo.
Slovenian: Bolniki z aktivno boleznijo, ki jo povzroči virus hepatitisa B, se ne smejo zdraviti z zdravilom Riximyo.
English: PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS Riximyo Alert Card for patients with non-oncology diseases
Slovenian: BESEDILO OPOZORILNE KARTICE BOLNIKA Z NEONKOLOŠKO INDIKACIJO Opozorilna kartica za bolnike, ki prejemajo zdravilo Riximyo za neonkološke bolezni
English: Medicines given before each Riximyo administration
Slovenian: Zdravila, ki jih boste dobili pred vsakim dajanjem zdravila Riximyo
English: The number of rituximab plus low-dose prednisone patients off prednisone therapy or on minimal therapy (prednisone dose of 10 mg or less per day) compared to standard-dose prednisone patients over the 24-month treatment period shows a steroid-sparing effect of rituximab (Figure 2).
Slovenian: Število bolnikov z rituksimabom in majhnim odmerkom prednizona (brez prednizonskega zdravljenja ali z minimalnim zdravljenjem (odmerek prednizona 10 mg ali manj na dan)) v primerjavi z bolniki s standardnim odmerkom prednizona v obdobju 24-mesečnega zdravljenja kaže, da rituksimab zmanjša potrebo po kortikosteroidih (slika 2).
English: Late neutropenia3
Slovenian: pozna nevtropenija3
English: Riximyo should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable.
Slovenian: Zdravilo Riximyo je treba dajati prvi dan vsakega cikla kemoterapije po uporabi glukokortikoidne sestavine kemoterapije, če jo shema vsebuje.
English: All physicians who are expected to prescribe Riximyo for non-oncology indications are provided with the following: - Product information - HCP educational leaflet - Patient educational leaflet
Slovenian: Vsi zdravniki, ki lahko predpišejo zdravilo Riximyo za neonkološke indikacije, prejmejo: - povzetek glavnih značilnosti zdravila - izobraževalni letak za zdravstvenega delavca - izobraževalni letak za bolnika
English: • unusual feelings of the skin - such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch
Slovenian: • neobičajni občutki na koži - na primer omrtvičenost, mravljinčenje, zbadanje, pekoč občutek, občutek gomazenja na koži, slabše zaznavanje dotika,
English: Table 14 Percentage of PV patients who achieved complete remission off corticosteroid therapy for two months or more at month 24 (Intent-to-Treat Population - PV)
Slovenian: Odstotek bolnikov z navadnim pemfigusom, ki so po 24 mesecih dosegli popolno remisijo brez kortikosteroidnega zdravljenja v obdobju dveh mesecev ali več (populacija z-namenom-zdravljenja - navadni pemfigus)
English: Rituximab is associated with infusion-related reactions, which may be related to release of cytokines and/or other chemical mediators.
Slovenian: Rituksimab lahko povzroči reakcije, povezane z infuzijo, ki nastanejo zaradi sprostitve citokinov in/ali drugih kemičnih mediatorjev.
English: • short term increase in the amount of some types of anti-bodies in the blood (called
Slovenian: • kratkotrajno povečanje količine nekaterih vrst protiteles v krvi (imenujemo jih imunoglobulini
English: Very Rare Not known aetiology, +acute bronchitis, +sinusitis, hepatitis B1
Slovenian: glivične okužbe, okužbe neznane etiologije, +akutni bronhitis, +sinuzitis, hepatitis B1
English: Immunoglobulins - IgM), chemical disturbances in the blood caused by break-down of dying cancer cells
Slovenian: IgM), snovi v krvi, ki nastajajo zaradi razgradnje odmirajočih rakavih celic,
English: The complete response rate after cycle 8 was 76.2% in the R-CHOP group and 62.4% in the CHOP group
Slovenian: Po 8 ciklih zdravljenja je bil popolni odgovor v skupini R-CHOP 76,2 %, v skupini CHOP pa 62,4 % (p = 0,0028).
English: The Patient educational leaflet about Riximyo contains the following key elements: - Detailed information on the risk of infections and PML - Information on the signs and symptoms of infections, especially PML, and the need to contact their doctor immediately if they experience any - The importance of sharing this information with their partner or caregiver - Information on the Patient Alert Card
Slovenian: Izobraževalni letak za bolnika o zdravilu Riximyo vsebuje naslednje ključne vsebine: - podrobne podatke o tveganju za okužbe in PML, - informacije o znakih in simptomih okužb, še posebno PML, in informacije o nujnosti, da nemudoma obvestijo svojega zdravnika, če izkusijo katerega od znakov ali simptomov,
English: Riximyo maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Slovenian: Vzdrževalno zdravljenje z zdravilom Riximyo je indicirano za zdravljenje bolnikov s folikularnimi limfomi, ki se odzovejo na indukcijsko zdravljenje.
English: Medicinal products for the treatment of hypersensitivity reactions, e.g. epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of Riximyo.
Slovenian: Zdravila za zdravljenje reakcij preobčutljivosti, npr. adrenalin, antihistaminiki in glukokortikoidi, morajo biti na voljo za takojšnjo uporabo, če bi se med dajanjem zdravila Riximyo pojavile alergijske reakcije.
English: What Riximyo looks like and contents of the pack
Slovenian: Izgled zdravila Riximyo in vsebina pakiranja
English: How Riximyo is given How it is given
Slovenian: Kako se daje zdravilo Riximyo Kako se zdravilo daje
English: Depending on the severity of the IRR and the required interventions, temporarily or permanently discontinue Riximyo.
Slovenian: Glede na resnost z infuzijo povezanih reakcij in potrebne ukrepe, je treba zdravilo Riximyo ukiniti ali ga začasno prekiniti.
English: Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with Riximyo.
Slovenian: Pri vseh bolnikih je treba pred začetkom zdravljenja z zdravilom Riximyo narediti presejalni test na virus hepatitisa B (HBV).
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis in disease remission or pemphigus vulgaris, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to Riximyo infusions to decrease the incidence and severity of infusion related reactions (IRRs).
Slovenian: Pri bolnikih z granulomatozo s poliangiitisom (Wegenerjevo granulomatozo), mikroskopskim poliangiitisom v remisiji ali navadnim pemfigusom je treba 30 minut pred pričetkom infundiranja zdravila Riximyo zaključiti z intravenskim dajanjem 100 mg metilprednizolona za zmanjšanje incidence in resnosti reakcij, povezanih z infuzijo.
English: A total of 810 patients (403 R-FC, 407 FC) for the first-line study (Table 10a and Table 10b) and 552 patients (276 R-FC, 276 FC) for the relapsed/refractory study (Table 11) were analysed for efficacy.
Slovenian: (403 R-FC, 407 FC) iz študije pri bolnikih v prvi liniji zdravljenja (preglednici 10a ter 10b) ter 552 bolnikov (276 R-FC, 276 FC) iz študije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje (preglednica 11).
English: Patients treated with Riximyo must be given the patient alert card with each infusion.
Slovenian: Bolniki, ki prejemajo zdravilo Riximyo, morajo ob vsaki infuziji dobiti opozorilno kartico.
English: • muscle problems - such as tight muscles, joint or muscle pain, back and neck pain
Slovenian: • težave z mišicami - na primer napete mišice, bolečine v sklepih ali mišicah, bolečine v hrbtu in vratu,
English: Riximyo contains sodium
Slovenian: Zdravilo Riximyo vsebuje natrij
English: albumin, B symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk ratios for event-free survival and overall survival (R-CHOP compared with CHOP) were less than 0.83 and 0.95 respectively.
Slovenian: Cooperative Oncology Group), koncentracija mikroglobulina ß2, koncentracija LDH, koncentracija albumina, B simptomi, obsežna bolezen, ekstranodalne lokalizacije, infiltracija kostnega mozga) je bilo razmerje tveganj za preživetje brez dogodkov za R-CHOP v primerjavi s CHOP manjše kot 0,83, za skupno preživetje pa manjše kot 0,95.
English: Riximyo is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Slovenian: Zdravilo Riximyo je indicirano za zdravljenje predhodno nezdravljenih bolnikov s III. in IV. stadijem folikularnih limfomov v kombinaciji s kemoterapijo.
English: • The active ingredient in Riximyo is called rituximab.
Slovenian: • Učinkovina zdravila Riximyo je rituksimab.
English: Riximyo should be administered as two 500 mg IV infusions separated by two weeks, followed by a 500 mg IV infusion every 6 months thereafter.
Slovenian: Zdravilo Riximyo je treba dati v dveh 500-mg intravenskih infuzijah, med katerima mora biti 2tedenski presledek; temu sledijo 500-mg intravenske infuzije na 6 mesecev.
English: If you are not sure, talk to your doctor, pharmacist or nurse before you are given Riximyo.
Slovenian: Če ste negotovi, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Riximyo.
English: Chemical and physical stability of Riximyo diluted in 5% glucose solution has been demonstrated for 24 hours at 2°C - 8°C and subsequently 12 hours at room temperature (≤25°C).
Slovenian: • Po aseptični razredčitvi v raztopini glukoze: Kemična in fizikalna stabilnost zdravila Riximyo, razredčenega v 5-odstotni raztopini glukoze, je bila dokazana za 24 ur pri temperaturi 2 °C - 8 °C in nato še 12 ur pri sobni temperaturi (≤ 25 °C).
English: In case of such an event with a suspected relationship to Riximyo, treatment should be permanently discontinued.
Slovenian: Če se pojavi tak neželen učinek z možno povezavo z zdravilom Riximyo, je treba zdravljenje trajno ukiniti.
English: Physicians should exercise caution when considering the use of Riximyo in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8).
Slovenian: Pri odločanju za uporabo zdravila Riximyo morajo biti zdravniki previdni pri bolnikih z anamnezo ponavljajočih se ali kroničnih okužb ali s sočasnimi boleznimi, zaradi katerih so lahko bolniki dodatno nagnjeni k resnim okužbam (glejte poglavje 4.8).
English: Response rate and CR rates analysed using Chi-squared Test. *: only applicable to patients achieving a CR, nPR, PR; NR: not reached n.a. not applicable **: only applicable to patients achieving a CR;
Slovenian: *: aplikabilno samo za bolnike, ki so dosegli CR, nPR (nodularni delni odgovor), PR; NR: nedoseženo; n.a. neaplikabilno **: aplikabilno samo za bolnike, ki so dosegli CR
English: The prepared Riximyo solution should be administered as an intravenous infusion through a dedicated line.
Slovenian: Pripravljeno raztopino zdravila Riximyo dajemo kot intravensko infuzijo skozi poseben kanal.
English: However, because maternal IgG is excreted in human milk, and rituximab was detectable in milk from lactating monkeys, women should not breast-feed while treated with Riximyo and for 12 months following Riximyo treatment.
Slovenian: A zaradi dejstva, da se materini IgG izločajo v materino mleko, in da so rituksimab našli v mleku doječih opic, ženske med zdravljenjem z zdravilom
English: Riximyo is provided in sterile, preservative-free, non-pyrogenic, single use vials.
Slovenian: Zdravilo Riximyo je dobavljeno v sterilnih, apirogenih vialah brez konzervansov za enkratno uporabo.
English: Experience from non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Summary of the safety profile
Slovenian: Izkušnje pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji Povzetek varnostnih značilnosti
English: • Riximyo will be given to you on the same day as your chemotherapy.
Slovenian: • Če prejemate zdravilo Riximyo skupaj s kemoterapijo, ga boste dobili isti dan kot kemoterapijo.
English: The most common infections in the rituximab group were herpes simplex and zoster infections, bronchitis, urinary tract infection, fungal infection and conjunctivitis.
Slovenian: Najpogostejše okužbe v skupini z rituksimabom so bile okužbe z virusoma herpes simpleks in herpes zoster, bronhitis, okužbe sečil, glivične okužbe in konjunktivitis.
English: Adverse drug reactions presented in Table 5 were adverse events which occurred at a rate of ≥ 5% among rituximab-treated PV patients, with a ≥ 2% absolute difference in incidence between the rituximab-treated group and the standard-dose prednisone group up to month 24.
Slovenian: zdravljenimi z rituksimabom, pojavili z ≥ 5-odstotnim deležem, absolutna razlika v njihovi pojavnosti med skupino z rituksimabom in skupino s standardnim odmerkom prednizona pa je bila do 24. meseca
English: • inflammation of blood vessels including those leading to skin symptoms
Slovenian: • simptomi vnetja žil, vključno s tistimi, ki vodijo v kožo, • odpoved dihanja,
English: • lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG) in the blood which help protect against infection
Slovenian: • zmanjšana imunost - zaradi manjše koncentracije protiteles, imenovanih imunoglobulini (IgG),
English: The recommended dosage of Riximyo for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total).
Slovenian: Priporočeno odmerjanje zdravila Riximyo za indukcijo remisije pri zdravljenju granulomatoze s poliangiitisom in mikroskopskega poliangiitisa je 375 mg/m2 telesne površine v intravenski infuziji 1-krat na teden 4 tedne (skupaj štiri infuzije).
English: Therefore, in patients with a known cardiac history, and those who experienced prior cardiopulmonary adverse reactions, the risk of cardiovascular complications resulting from infusion reactions should be considered before treatment with Riximyo and patients closely monitored during administration.
Slovenian: Pred zdravljenjem z zdravilom Riximyo moramo pri bolnikih, z znanimi boleznimi srca in tistih, pri katerih so v preteklosti opazili kardio-pulmonalne neželene učinke, razmisliti o možnih kardiovaskularnih zapletih, ki lahko nastanejo kot posledica reakcij, povezanih z infuzijo, bolnike pa med dajanjem zdravila skrbno nadzorovati.
English: In a prospective, open label, international, multi-centre, phase III trial, 465 patients with relapsed/refractory follicular lymphoma were randomised in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone; n=231) or rituximab plus CHOP (R-CHOP, n=234).
Slovenian: Ponovitev folikularnih limfomov ali neodzivna bolezen V prospektivnem, odprtem, mednarodnem, multicentričnem preskušanju faze III je bilo 465 bolnikov, pri katerih so se folikularni limfomi ponovili ali se niso odzvali na zdravljenje, randomiziranih v prvi del indukcijskega zdravljenja s CHOP (ciklofosfamid, doksorubicin, vinkristin, prednizolon, n = 231) ali zdravljenje z rituksimabom in CHOP (R-CHOP, n = 234).
English: Chemical and physical stability of Riximyo diluted in 0.9% sodium chloride solution has been demonstrated for 30 days at 2°C - 8°C and subsequently 24 hours at room temperature (≤25°C).
Slovenian: • Po aseptični razredčitvi v raztopini natrijevega klorida: Kemična in fizikalna stabilnost zdravila Riximyo, razredčenega v 0,9-odstotni raztopini natrijevega klorida, je bila dokazana za 30 dni pri temperaturi 2 °C - 8 °C in nato še 24 ur pri sobni temperaturi (≤ 25 °C).
English: R-CVP led to a significant benefit over CVP for the primary endpoint, time to treatment failure (27 months vs. 6.6 months, p < 0.0001, log-rank test).
Slovenian: R-CVP je imela glede primarnega opazovanega dogodka (časa do neuspeha zdravljenja) značilno prednost pred skupino CVP (27 mesecev v primerjavi s 6,6 meseca, p < 0,0001, log-rank test).
English: Each course of treatment is made up of two separate infusions which are given 2 weeks apart.
Slovenian: d) Če se zdravite zaradi navadnega pemfigusa Vsak cikel zdravljenja obsega dve ločeni infuziji, ki ju boste dobili v presledku 2 tednov.
English: • low number of white blood cells, with or without fever or blood cells called “platelets”
Slovenian: • bakterijske ali virusne okužbe, bronhitis, • majhno število belih krvnih celic (z zvišano telesno temperaturo ali brez nje) ali krvnih celic, ki jih imenujemo trombociti (krvne ploščice),
English: All patients treated with Riximyo for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris must be given the patient alert card with each infusion.
Slovenian: Vsem bolnikom, ki se z zdravilom Riximyo zdravijo zaradi revmatoidnega artritisa, granulomatoze s poliangiitisom, mikroskopskega poliangiitisa ali navadnega pemfigusa, je treba ob vsaki infuziji dati opozorilno kartico (glejte Dodatek IIIA - Označevanje).
English: Figure 1:
Slovenian: Preglednica 1.
English: Data in approximately 180 patients pre-treated with rituximab have demonstrated clinical benefit (including CR) and are supportive for rituximab re-treatment.
Slovenian: dokazujejo klinično korist (vključno s CR) in podpirajo ponovno zdravljenje z rituksimabom.
English: Sepsis, +pneumonia, +febrile infection, +herpes zoster, +respiratory tract infection, fungal infections, infections of unknown
Slovenian: +febrilna okužba, +herpes zoster, +okužbe dihal,
English: The HCP educational leaflet about Riximyo for non-oncology indications contains the following key elements: - The need for close supervision during administration in an environment where full resuscitation facilities are immediately available - The need to check, prior to Riximyo treatment, for infections, for immunosuppression, for prior/current medication affecting the immune system, and recent history of, or planned, vaccination, and a history of infusion-related reaction - The need to monitor patients for infections, especially PML, during and after Riximyo treatment - Detailed information on the risk of PML, the need for timely diagnosis of PML and appropriate measures to diagnose PML - The need to advise patients on the risk of infections and PML, including the symptoms to be aware of and the need to contact their doctor immediately if they experience any - The need to provide patients with the Patient Alert Card with each infusion
Slovenian: Izobraževalni letak za zdravstvenega delavca o zdravilu Riximyo za neonkološke indikacije vsebuje naslednje ključne vsebine: - informacije o nujnosti skrbnega nadzora med aplikacijo v okolju, kjer so vsi pripomočki za oživljanje nemudoma na voljo, - informacije o nujnosti, da pred dajanjem zdravila Riximyo preverijo, ali je bolnik morda okužen, imunsko oslabljen, ali jemlje zdravila, ki vplivajo na imunski sistem, ali jih je jemal v preteklosti, ali se je nedavno cepili oziroma to namerava, in anamnezo reakcij, povezanih z infuzijo
English: • If you are having Riximyo alone
Slovenian: • Če prejemate samo zdravilo Riximyo,
English: This is a disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes.
Slovenian: Ne-Hodgkinov limfom je bolezen limfatičnega tkiva (ta je del imunskega sistema), ki prizadene vrsto belih krvnih celic, limfocite B. Zdravilo Riximyo lahko uporabljamo samostojno ali skupaj z drugimi zdravili, ki jih imenujemo kemoterapija.
English: Since hypotension may occur during rituximab infusion, consideration should be given to withholding anti-hypertensive medicinal products 12 hours prior to the Riximyo infusion.
Slovenian: Ker se med infuzijo rituksimaba lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo zdravila Riximyo bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
English: • swelling of the stomach.
Slovenian: • bolečina v trebuhu,
English: • changes in the rhythm of the heart, or the heart beating faster than normal
Slovenian: • povečanje količine kalija v krvi, • spremembe v srčnem ritmu ali hitrejše (kot je običajno) bitje srca.